Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately Held Companies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Oct. 05, 2023	Dec. 01, 2020
Revenue from Contract with Customer, Excluding Assessed Tax	$ 2,898,806	$ 2,930,303
Alphazyme [Member]
Proceeds from Sale, Maturity and Collection of Investments	1,300,000
Alphazyme [Member]
Ownership Percentage				1.99%
Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	2,545,865	2,683,244
Inzymes Agreement APS [Member]
Non-refundable Upfront Payment, Received	600,000		$ 600,000
Revenue from Contract with Customer, Excluding Assessed Tax	110,000
A Global Food Ingredient Company [Member] \| Research and Development [Member] \| Purchase Provision Terms [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	631,000	790,000
Janssen Pharmaceutical Companies [Member]
Deferred License Revenue	353,000	176,000
Accounts Receivable, after Allowance for Credit Loss	145,000	121,000
Janssen Pharmaceutical Companies [Member] \| Research and Development [Member]
Revenue from Contract with Customer, Excluding Assessed Tax	$ 520,000	$ 539,000